Mark Fletcher - Generex Biotechnology President CEO, General Counsel, Director
GNBTDelisted Stock | USD 0.0001 0.00 0.00% |
CEO
Mr. Mark A. Fletcher, Esquire, is Mr. Fletcher serves as the Companys Executive Vice President General Counsel, Secretary. of Generex Biotechnology Corporationrationration. He served as our President and Chief Executive Officer from September, 2010 through January 17, 2017. Mr. Fletcher served as a member of the Board of Directors from March 2011 through January 17, 2017. Mr. Fletcher was our Executive VicePresident and General Counsel from April, 2003 until September, 2010, and he resumed those roles as of January 17, 2017. Prior to joining Generex, Mr. Fletcher was engaged in the private practice of law as a partner at Goodman and Carr LLP, a leading Toronto law firm. Mr. Fletcher was previously a partner at Brans, Lehun, Baldwin LLP, a law firm in Toronto since 2017.
Age | 50 |
Tenure | 7 years |
Phone | 416 364 2551 |
Web | https://generex.com/index.html |
Generex Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.4384) % which means that it has lost $0.4384 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.7271) %, meaning that it created substantial loss on money invested by shareholders. Generex Biotechnology's management efficiency ratios could be used to measure how well Generex Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 499.66 K in liabilities. Generex Biotechnology has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Generex Biotechnology until it has trouble settling it off, either with new capital or with free cash flow. So, Generex Biotechnology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Generex Biotechnology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Generex to invest in growth at high rates of return. When we think about Generex Biotechnology's use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 8 records | CEO Age | ||
Marshall Loeb | EastGroup Properties | 62 | |
Charles Prober | NETGEAR | 53 | |
Yaron Ravkaie | Radcom | 48 | |
David Ripstein | Radcom | 47 | |
Patrick Goepel | Asure Software | 62 | |
Peter Lau | FARO Technologies | 44 | |
Michael Burger | FARO Technologies | 65 | |
Alexander Edgarov | InFintT Acquisition Corp | 47 |
Management Performance
Return On Equity | -17.73 | |||
Return On Asset | -0.44 |
Generex Biotechnology Leadership Team
Elected by the shareholders, the Generex Biotechnology's board of directors comprises two types of representatives: Generex Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Generex. The board's role is to monitor Generex Biotechnology's management team and ensure that shareholders' interests are well served. Generex Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Generex Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eric Hofe, VP, Director and President of Antigen Express, Inc | ||
James Anderson, Independent Director | ||
Jacob Dagan, Executive Vice President Business Development. | ||
Gary Lyman, Independent Director | ||
Mark Prioletti, Independent Interim Director | ||
Andrew Ro, Senior Vice President of Investments, Chief Investment Officer, Director | ||
Kevin Centofanti, Director | ||
Mark Fletcher, President CEO, General Counsel, Director | ||
Terry Thompson, Chief Officer | ||
Craig Eagle, Independent Director | ||
Lawrence Salvo, Director | ||
Marshal Schictman, Executive Vice President General Counsel | ||
Jason Terrell, Chief Scientific Officer, Chief Medical Officer | ||
David Brusegard, COO and Secretary | ||
Omar Gzouli, Independent Interim Director | ||
Andrew Greene, Director | ||
Richard Purcell, Senior Vice President of Research & Drug Development. | ||
Esq CPA, Chief Officer | ||
Joseph Moscato, Chairman of the Board and Presidentident, CEO | ||
Mark Corrao, CFO, Treasurer | ||
Brian McGee, Independent Director | ||
Anthony Dolisi, Chief Officer | ||
Todd Falls, IR Contact Officer | ||
Stephen Fellows, CFO | ||
Michelle Starr, Chief Officer |
Generex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Generex Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -17.73 | |||
Return On Asset | -0.44 | |||
Operating Margin | (49.52) % | |||
Current Valuation | 7.68 M | |||
Shares Outstanding | 118.45 M | |||
Shares Owned By Institutions | 0.02 % | |||
Number Of Shares Shorted | 211.98 K | |||
Price To Earning | 5.59 X | |||
Price To Sales | 0.10 X | |||
Revenue | 2.66 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Generex Biotechnology information on this page should be used as a complementary analysis to other Generex Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Generex OTC Stock
If you are still planning to invest in Generex Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Generex Biotechnology's history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Transaction History View history of all your transactions and understand their impact on performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |